Search Results

You are looking at 91 - 100 of 858 items for :

  • Refine by Access: All x
Clear All
Full access

Part I: The Role of Maintenance Therapy in Patients With Multiple Myeloma Undergoing Autologous Hematopoietic Stem Cell Transplantation

Philip L. McCarthy

: 825 – 831 . 4 Richardson PG Schlossman RL Weller E . Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma . Blood 2002 ; 100 : 3063 – 3067 . 5 Rajkumar SV

Full access

Hodgkin Lymphoma, Version 2.2012 Featured Updates to the NCCN Guidelines

Richard T. Hoppe, Ranjana H. Advani, Weiyun Z. Ai, Richard F. Ambinder, Patricia Aoun, Celeste M. Bello, Philip J. Bierman, Kristie A. Blum, Robert Chen, Bouthaina Dabaja, Ysabel Duron, Andres Forero, Leo I. Gordon, Francisco J. Hernandez-Ilizaliturri, Ephraim P. Hochberg, David G. Maloney, David Mansur, Peter M. Mauch, Monika Metzger, Joseph O. Moore, David Morgan, Craig H. Moskowitz, Matthew Poppe, Barbara Pro, Jane N. Winter, Joachim Yahalom, and Hema Sundar

drug conjugates (ADC) and monoclonal antibodies have shown promising results for patients with relapsed or progressive disease. 3 , 4 The following sections of these NCCN Guidelines Insights include the major discussion points from the 2011 Hodgkin

Full access

Acute Lymphoblastic Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology

Patrick A. Brown, Bijal Shah, Anjali Advani, Patricia Aoun, Michael W. Boyer, Patrick W. Burke, Daniel J. DeAngelo, Shira Dinner, Amir T. Fathi, Jordan Gauthier, Nitin Jain, Suzanne Kirby, Michaela Liedtke, Mark Litzow, Aaron Logan, Selina Luger, Lori J. Maness, Stephanie Massaro, Ryan J. Mattison, William May, Olalekan Oluwole, Jae Park, Amanda Przespolewski, Sravanti Rangaraju, Jeffrey E. Rubnitz, Geoffrey L. Uy, Madhuri Vusirikala, Matthew Wieduwilt, Beth Lynn, Ryan A. Berardi, Deborah A. Freedman-Cass, and Mallory Campbell

Cox regression analysis reported in the MRC UKALL XII/ECOG E2993 study, t(8;14), low hypodiploidy/near triploidy, and complex karyotype remained significant independent predictors for risk of relapse or death; the prognostic impact of these cytogenetic

Full access

Non-Hodgkin’s Lymphomas, Version 4.2014

Andrew D. Zelenetz, Leo I. Gordon, William G. Wierda, Jeremy S. Abramson, Ranjana H. Advani, C. Babis Andreadis, Nancy Bartlett, John C. Byrd, Myron S. Czuczman, Luis E. Fayad, Richard I. Fisher, Martha J. Glenn, Nancy Lee Harris, Richard T. Hoppe, Steven M. Horwitz, Christopher R. Kelsey, Youn H. Kim, Susan Krivacic, Ann S. LaCasce, Auayporn Nademanee, Pierluigi Porcu, Oliver Press, Rachel Rabinovitch, Nishitha Reddy, Erin Reid, Ayman A. Saad, Lubomir Sokol, Lode J. Swinnen, Christina Tsien, Julie M. Vose, Joachim Yahalom, Nadeem Zafar, Mary Dwyer, and Hema Sundar

(n=40; median age, 70 years), 50% were previously untreated, 93% had stage III/IV disease and 49% had high-risk MIPI scores. Patients with relapsed/refractory disease (n=20) had all previously received rituximab-containing therapies. 38 Among

Full access

Management of Multiple Myeloma

Shaji K. Kumar

's presentation covered the landscape of MM, from solitary bone lesions to smoldering disease to the primary treatment of active myeloma and relapsed disease. Solitary Plasmacytoma Solitary plasmacytomas—biopsy-proven solitary lesions of bone or soft

Full access

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2024

William G. Wierda, Jennifer Brown, Jeremy S. Abramson, Farrukh Awan, Syed F. Bilgrami, Greg Bociek, Danielle Brander, Matthew Cortese, Larry Cripe, Randall S. Davis, Herbert Eradat, Bita Fakhri, Christopher D. Fletcher, Sameh Gaballa, Muhammad Saad Hamid, Brian Hill, Paul Kaesberg, Brad Kahl, Manali Kamdar, Thomas J. Kipps, Shuo Ma, Claudio Mosse, Shazia Nakhoda, Sameer Parikh, Andrew Schorr, Stephen Schuster, Madhav Seshadri, Tanya Siddiqi, Deborah M. Stephens, Meghan Thompson, Chaitra Ujjani, Riccardo Valdez, Nina Wagner-Johnston, Jennifer A. Woyach, Hema Sundar, and Mary Dwyer

than del(17p) or TP53 mutation in patients with CLL treated with ibrutinib-based regimens. 45 – 48 It should be noted that in these studies, del(17p) often correlated with the presence of CK. Among patients with relapsed/refractory CLL treated with

Full access

Hodgkin Lymphoma, Version 2.2015

Richard T. Hoppe, Ranjana H. Advani, Weiyun Z. Ai, Richard F. Ambinder, Patricia Aoun, Celeste M. Bello, Cecil M. Benitez, Philip J. Bierman, Kristie A. Blum, Robert Chen, Bouthaina Dabaja, Andres Forero, Leo I. Gordon, Francisco J. Hernandez-Ilizaliturri, Ephraim P. Hochberg, Jiayi Huang, Patrick B. Johnston, Nadia Khan, David G. Maloney, Peter M. Mauch, Monika Metzger, Joseph O. Moore, David Morgan, Craig H. Moskowitz, Carolyn Mulroney, Matthew Poppe, Rachel Rabinovitch, Stuart Seropian, Christina Tsien, Jane N. Winter, Joachim Yahalom, Jennifer L. Burns, and Hema Sundar

treatment and no treatment-related deaths or secondary leukemia were reported. Among 16 patients who experienced disease relapse, the freedom from second relapse was 69% at 5 years. Other investigators have also confirmed that the Stanford V regimen is

Full access

Management of Advanced Germ Cell Cancer in Patients With Unfavorable Prognosis

Kim Margolin

. J Clin Oncol 1996 ; 14 : 2631 – 2637 . 8 Margolin KA Doroshow JH Frankel P . Taxol-based high-dose chemotherapy with autologous stem cell rescue for relapsed germ cell cancer . (Submitted for publication) . 9 Broun ER

Full access

Small Cell Lung Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology

Apar Kishor P. Ganti, Billy W. Loo Jr., Michael Bassetti, Collin Blakely, Anne Chiang, Thomas A. D'Amico, Christopher D'Avella, Afshin Dowlati, Robert J. Downey, Martin Edelman, Charles Florsheim, Kathryn A. Gold, Jonathan W. Goldman, John C. Grecula, Christine Hann, Wade Iams, Puneeth Iyengar, Karen Kelly, Maya Khalil, Marianna Koczywas, Robert E. Merritt, Nisha Mohindra, Julian Molina, Cesar Moran, Saraswati Pokharel, Sonam Puri, Angel Qin, Chad Rusthoven, Jacob Sands, Rafael Santana-Davila, Michael Shafique, Saiama N. Waqar, Kristina M. Gregory, and Miranda Hughes

decreased in older patients treated with PCI compared with younger patients regardless of stage. 149 Surveillance for Relapse Although SCLC is very responsive to initial treatment, most patients relapse with relatively resistant disease (see also

Full access

Use of PARP Inhibitors for Ovarian Cancer

Presented by: Deborah K. Armstrong

there is no information on whether these benefits would be seen in patients who had previously received PARP inhibitors. Recurrent Disease Active treatment of relapsed disease with PARP inhibitors has also been well tested in BRCA -positive